Bionano Genomics, Inc. (BNGO) is a leading, high-growth life sciences tech company that operates in the biotechnology and genomic research space. It is best known for its innovative contributions to the genomic industry, by providing robust tools and services that enhance researchers' understanding of the genomics of human diseases.
The company is most recognized for its development of Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and enhance the study of changes in chromosomes (structural variations). This revolutionary system consists of an instrument, chip consumables, reagents, and a suite of data analysis tools. This cutting-edge technology has been associated with unlocking new areas of disease research, notably in the field of neurodegenerative disorders, leukemia, infertility, and others.
Based in San Diego, California, Bionano Genomics, based on their mission statement, ‘makes big things possible in genomics’, by delivering essential genomic information that isn't available with other approaches to help researchers find the truth in genomics. However, Bionano is not just limited to instrument production, but also offers data-analysis services and genome mapping services for various genotype-phenotype studies, disease gene-research, and genome assemblies.
Moreover, beyond being an industry leader in life sciences, Bionano Genomics also extends its commitment to positively impacting society by being socially responsible. The firm operates under a rigorous code of ethics and business conduct, placing a strong emphasis on integrity, transparency, and fairness. It also values diversity and inclusion, fostering a culture that encourages innovative thinking from all voices, backgrounds, and perspectives.
While the biotechnology sector is highly competitive, Bionano Genomics has positioned itself at the intersection of technology and biology, and by doing so, it has solidified its reputation as a leader in the field of genomics. With its pioneering approach to genomic research, the company is committed to exploring the harnessing of molecular diagnostics for the improvement of human health. Through its groundbreaking initiatives, Bionano Genomics is ideally situated to continue leading the charge in genomic discoveries as it propels the field further into the future.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
BioNano Genomics, Inc. (NASDAQ: BNGO) has filed a $400 million mixed shelf offering, which includes common stock, preferred stock, debt securities, warrants, and units. The company's stock is currently priced at $1.15, and the overall analyst rating is a "SELL". This filing is significant for serious traders looking at equity offerings.
Bionano Genomics, Inc. (Nasdaq: BNGO) has announced that it will report its financial results for the third quarter of 2026 on Tuesday, November 10, 2026. The company will host a conference call and live webcast at 4:30 p.m. Eastern Time to discuss these results and provide an update on recent corporate progress. A replay of the event will be available on Bionano's investor relations website for at least 30 days.
Bionano Genomics Inc. (NASDAQ: BNGO) shares surged Tuesday due to a multi-year growth strategy presented at the H.C. Wainwright 28th Annual Global Investment Conference. The company projected significant revenue growth for 2026 and 2027, driven by the transition of its optical genome mapping technology into routine clinical use. Additionally, recent regulatory approvals, including proposed Medicare coverage and New York State Department of Health clinical approval, further validated the platform and contributed to the bullish sentiment.